COMMUNIQUÉS West-GlobeNewswire

AscellaHealth Expands Leadership Team to Accelerate Growth, Strengthen Operations and Advance Patient-Centric Solutions

25/02/2025 - 19:00

BERWYN, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- AscellaHealth , a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today announced the appointment of two senior leaders: [...]

GT Biopharma Announces Exercise of Warrants

25/02/2025 - 20:00

SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company [...]

Capital Increase in Genmab as a Result of Employee Warrant Exercise

25/02/2025 - 20:30

Company Announcement COPENHAGEN, Denmark; February 25, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,058 shares as a consequence of the exercise of employee warrants. The increase is effected [...]

Lipozem Under Review: The Truth About Lipozem and Triple-BHB Power for Weight Loss

25/02/2025 - 21:27

LAKELAND, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Lipozem is a groundbreaking solution designed to support individuals in shedding stubborn weight without resorting to exhaustive diets or intense workouts. In today’s [...]

Merus annonce sa participation aux prochaines journées Investisseurs

25/02/2025 - 21:55

UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 25 févr. 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une société d’oncologie au stade clinique développant des anticorps multispécifiques de pleine [...]

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

25/02/2025 - 22:00

WESTLAKE VILLAGE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Q4 2024 net product revenue for ZORYVE® (roflumilast) was $69.4 million, a 413% increase compared to Q4 of 2023 and a 55% increase compared to Q3 of 2024; [...]

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

25/02/2025 - 22:00

UZEDY is currently approved in the US as a subcutaneous long-acting injectable (LAI) for use every one or two months for the treatment of schizophrenia in adults 1 LAI treatment options may help address unmet needs of [...]

DBV Technologies participera au prochain congrès conjoint AAAAI/WAO

25/02/2025 - 22:01

Châtillon, France, le 25 février (22 :30 CEST) 2025 DBV Technologies participera au prochain congrès conjoint AAAAI/WAO DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), une société [...]

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

25/02/2025 - 22:01

Châtillon, France, February 25, 2025 DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage [...]

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

25/02/2025 - 22:01

-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity [...]

Xenon to Present at the 45th Annual TD Cowen Healthcare Conference

25/02/2025 - 22:01

VANCOUVER, British Columbia and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering [...]

Supernus Announces Fourth Quarter and Full Year 2024 Financial Results

25/02/2025 - 22:01

Fourth quarter 2024 net sales of Qelbree ® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of Qelbree increased 72% to $241.3 million, compared to full year 2023. Fourth [...]

PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results

25/02/2025 - 22:02

SAN JOSE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in [...]

OraSure Reports Fourth Quarter 2024 Financial Results

25/02/2025 - 22:05

BETHLEHEM, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for [...]

Bolt Biotherapeutics to Participate in Upcoming March Conferences

25/02/2025 - 22:05

REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that [...]

Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025

25/02/2025 - 22:05

CARLSBAD, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2024, before the market [...]

RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 Guidance

25/02/2025 - 22:05

ALISO VIEJO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced [...]

Merit Medical Reports Fourth Quarter and Full Year 2024 Results and Issues Fiscal Year 2025 Guidance

25/02/2025 - 22:05

Fourth Quarter Highlights† Reported revenue of $355.2 million, up 9.4% Constant currency revenue* and constant currency revenue, organic* up 10.1% and up 6.1%, respectively GAAP operating margin of 10.3%, compared to 10 [...]

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

25/02/2025 - 22:05

Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively Ended 2024 with $531.7 million in cash, cash equivalents and short-term investments Company [...]